CAR-T Cell TherapyEarly Phase 1NCT05858684
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
A Early Phase 1 study testing GC012F injection in people with CAR-T Cell Therapy, run by RenJi Hospital at 1 site in China.
Trial summary
This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- CAR-T Cell Therapy
- What is being tested?
- GC012F injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 1 siteChina
- Study dates
- 11 May 2023to 10 Jun 2029
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18-70 years old;
- Total score ≥ 10 on the EULAR/ACR 2019 SLE classification criteria;
- LLDAS response criteria are not achieved after administration with at least two immunosuppressants (including, but not limited to, azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, ciclosporin and iguratimod) and/or at least one approved biological agent for more than 6 months.
- SELENA-SLEDAI≥8;
- Patients with CD19+ B-cell;
- Hemoglobin≥85 g/L;
Show all 14Show fewer
- WBC≥2.5×10^9/L
- NEUT≥1×10^9/L;
- BPC≥50×10^9/L;
- AST/ALT below 2 times the upper limit of normal; Creatinine clearance ≥30 mL/min; blood bilirubin ≤2.0 mg/dl; echocardiography indicates that the ejection fraction is ≥50%;
- Adequate venous access for apheresis, and no other contraindications for leukapheresis;
- Women of childbearing age should have a negative serum or urine pregnancy test at screening and baseline. Subjects agree to take effective contraceptive measures during the trial until at least 1 year after CAR-T cells infusion.
- Agree to attend follow-up visits as required;
- Voluntary participation and informed consent signed by the patient or his/her legal/authorized representative;
Who cannot join
- Renal disease: severe lupus nephritis (serum creatinine > 2.5 mg/dL or 221 μmol/L) within 8 weeks prior to leukapheresis, or subjects who need hemodialysis;
- CNS disease: including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident [CVA], encephalitis or CNS vasculitis, psychiatric patients with depression or suicidal thoughts;
- Patients with serious lesions and history of present illness of vital organs such as heart, liver, kidney and blood and endocrine system;
- Patients with immunodeficiency, uncontrolled active infections and active or recurrent peptic ulcers;
- Received immunosuppressive therapy within 1 week prior to leukapheresis;
- Patients with HIV infection; Active infection of hepatitis B virus or hepatitis C virus; Patients with syphilis infection;
Show all 17Show fewer
- The presence or suspicion of an active fungal, bacterial, viral or other infection that cannot be controlled during screening;
- Received live vaccine treatment within 4 weeks prior to screening;
- Severe allergies or hypersensitivity;
- Contraindication to cyclophosphamide in combination with fludarabine;
- Subjects who have undergone major surgery within 2 weeks prior to signing the informed consent form, or who are scheduled to have surgery (other than local anesthetic surgery) during the trial or within 2 weeks of the infusion;
- cannula or drainage tubes other than central venous catheters;
- Pregnant or lactating women, or subjects who plan to have children within 1 year of treatment;
- Subjects with prior CD19 or BCMA-targeted therapy
- Participated in any clinical study within 3 months prior to enrollment
- Subjects with malignant tumour, except for Non-melanoma Skin Cancer with PFS>5yr; Cervical Cancer in situ; Bladder Cancer; Breast Cancer;
- Any situations that the investigator believes the patients are not suitable for the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University
Shanghai, Shanghai Municipality, 200001
Qiong Fu, MD, 86-13585603288, fuqiong5@163.com
Chunmei Wu, MD, 86-15800605296, wuchunmei_1988@163.com
About this study
This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.
Read the detailed description
Systemic lupus erythematosus (SLE) is a kind of autoimmune diseases mediated by autoantibody-forming immune complexes, which involving multiple systems and organs.
Autoreactive B cells can self-activate and differentiate into plasma cells releasing large amounts of autoantibodies, while they can also present their own antigens to autoimmune T cells, thus activating T cells and promoting the release of inflammatory factors.
Traditional SLE treatment aims at long-term remission, while, CD19- BCMA CAR-T cells can theoretically completely deplete abnormal antibody-producing B cells, allowing immune rebuilding and restoring the patient's normal immune function, achieving drug-free survival, which fully reflects the application prospects of CAR-T therapy in SLE.
- Conditions
- CAR-T Cell Therapy
- Being tested
- GC012F injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GC012F injectionDrug
Also called CD19-BCMA CAR-T cells
Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0.
| Study group | Role | What they receive |
|---|---|---|
| GC012F injection (CD19-BCMA CAR-T cells) | Experimental | Dose escalation phase:
DL-1：0.5±20%×10^5/kg, DL1：1±20%×10^5/kg, DL2：2±20%×10^5/kg DL3：3±20%×10^5/kg Receives: Drug: GC012F injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of subjects with DLT
DLT definition is dose-limiting toxicity
Measured: Within 28 days after GC012F injection infusion
The proportion of subjects with adverse events
All adverse events were evaluated according to NCI-CTCAE v5.0 criteria
Measured: Within 12 weeks after GC012F injection infusion
Secondary outcomes (2)
Proportion of subjects achieving SRI-4
SELEAN-SLEDAI，BILAG，PGA
Measured: 4, 8, 12 and 24 weeks after GC012F injection infusion
Number of CAR-T cells and CAR gene copies in subjects'blood and bone marrow (if applicable)
Test method: flow cytometry and qPCR
Measured: After GC012F injection infusion [day 4, 7, 10, 14 and week 4, 8, 12, 24]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2023
- Study start11 May 2023
- Primary completion10 Aug 2028 (estimated)
- Study completion10 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CAR-T Cell TherapyStudies of the same condition, open and under way.
- More trials run by RenJi HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- RenJi Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- Responsible party
- Principal investigator, Qiong Fu, RenJi Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05858684
- Sponsor's protocol ID
- GC012F-615
- Status last verified
- May 2026
- First submitted
- 5 May 2023
- Last updated
- 1 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
- ClinicalTrials.gov ID
- NCT05858684
- Acronym / sponsor ID
- GC012F-615
- Conditions
- CAR-T Cell Therapy
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- RenJi HospitalUniversity, hospital or other
- Collaborators
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- Study start
- 11 May 2023 (actual)
- Primary completion
- 10 Aug 2028 (estimated)
- Study completion
- 10 Jun 2029 (estimated)
- First posted
- 15 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.
Detailed description
Systemic lupus erythematosus (SLE) is a kind of autoimmune diseases mediated by autoantibody-forming immune complexes, which involving multiple systems and organs.
Autoreactive B cells can self-activate and differentiate into plasma cells releasing large amounts of autoantibodies, while they can also present their own antigens to autoimmune T cells, thus activating T cells and promoting the release of inflammatory factors.
Traditional SLE treatment aims at long-term remission, while, CD19- BCMA CAR-T cells can theoretically completely deplete abnormal antibody-producing B cells, allowing immune rebuilding and restoring the patient's normal immune function, achieving drug-free survival, which fully reflects the application prospects of CAR-T therapy in SLE.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| GC012F injection (CD19-BCMA CAR-T cells) | Experimental | Drug: GC012F injectionDose escalation phase: DL-1：0.5±20%×10^5/kg, DL1：1±20%×10^5/kg, DL2：2±20%×10^5/kg DL3：3±20%×10^5/kg |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- 18-70 years old;
- Total score ≥ 10 on the EULAR/ACR 2019 SLE classification criteria;
- LLDAS response criteria are not achieved after administration with at least two immunosuppressants (including, but not limited to, azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, ciclosporin and iguratimod) and/or at least one approved biological agent for more than 6 months.
- SELENA-SLEDAI≥8;
- Patients with CD19+ B-cell;
Key exclusion criteria (17 listed)
- Renal disease: severe lupus nephritis (serum creatinine > 2.5 mg/dL or 221 μmol/L) within 8 weeks prior to leukapheresis, or subjects who need hemodialysis;
- CNS disease: including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident [CVA], encephalitis or CNS vasculitis, psychiatric patients with depression or suicidal thoughts;
- Patients with serious lesions and history of present illness of vital organs such as heart, liver, kidney and blood and endocrine system;
- Patients with immunodeficiency, uncontrolled active infections and active or recurrent peptic ulcers;
- Received immunosuppressive therapy within 1 week prior to leukapheresis;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GC012F injectionAlso: CD19-BCMA CAR-T cellsEach subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0. | Drug | GC012F injection (CD19-BCMA CAR-T cells) |
Primary outcome
The proportion of subjects with DLT
Time frame: Within 28 days after GC012F injection infusion
DLT definition is dose-limiting toxicity
The proportion of subjects with adverse events
Time frame: Within 12 weeks after GC012F injection infusion
All adverse events were evaluated according to NCI-CTCAE v5.0 criteria
2 secondary outcomes
Proportion of subjects achieving SRI-4
Time frame: 4, 8, 12 and 24 weeks after GC012F injection infusion
Number of CAR-T cells and CAR gene copies in subjects'blood and bone marrow (if applicable)
Time frame: After GC012F injection infusion [day 4, 7, 10, 14 and week 4, 8, 12, 24]
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for CAR-T Cell Therapy
Active, not recruitingPhase 2
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
B Cell ALL, B-Cell Lymphoma
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
RecruitingPhase 1
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Relapsed/Refractory AL Amyloidosis
RecruitingPhase 1
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Mesothelioma, Neoplasms
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing GC012F injection in people with CAR-T Cell Therapy, run by RenJi Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Qiong Fu, PhD (13585603288, fuqiong5@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of subjects with DLT (time frame: Within 28 days after GC012F injection infusion). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.